Fenwick Represents Mavupharma in its Acquisition by AbbVie

Fenwick & West represented Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer, in its announced acquisition by AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies.

More information about Mavupharma’s acquisition by AbbVie can be obtained from the press release.

The Fenwick transaction team included corporate partners Matthew Rossiter and Ethan Skerry and associates Chris Gorman, Joanna Xu, Myles Gutenkunst, Vincent Sheu and Joshua Fuller; executive compensation and employee benefits partner Matt Cantor and associate Hans Andersson; technology transactions partner Jake Handy and Pinar Bailey; and tax partner Larissa Neumann and associates Timmoney Ng and Ora Grinberg.